Showing results (91-100 of 858) with videos related to
Sort By:
Pageof 86
Rheumatology (Oxford, England)|November 19, 2003
The 5-yr HAQ-disability is related to the first year's changes in the narrowing, rather than erosion score in patients with recent-onset rheumatoid arthritisJean Francis Maillefert, Bernard Combe, Philippe Goupille, et al.Annals of the Rheumatic Diseases|September 4, 2017
Optimal methotrexate dose is associated with better clinical outcomes than non-optimal dose in daily practice: results from the ESPOIR early arthritis cohortCécile Gaujoux-Viala, Nathalie Rincheval, Maxime Dougados, et al.The Journal of Rheumatology|December 7, 2005
Concomitant therapies as an outcome measure. Part 1: DrugsLaure Gossec, Robert B M Landewé, Jean-Francis Maillefert, et al.Current Rheumatology Reports|May 5, 2010
Application of the GRAPPA psoriatic arthritis treatment recommendations in clinical practiceAizad Mumtaz, Oliver FitzGeraldExpert Review of Clinical Immunology|January 7, 2016
Psoriatic arthritis: complexities, comorbidities and implications for the clinicMuhammad Haroon, Oliver FitzGeraldThe Journal of Rheumatology. Supplement|July 4, 2012
Pathogenetic overview of psoriatic diseaseMuhammad Haroon, Oliver FitzgeraldCurrent Opinion in Rheumatology|May 16, 2020
MHC class I associations beyond HLA-B27: the peptide binding hypothesis of psoriatic arthritis and its implications for disease pathogenesisRobert Winchester, Oliver FitzGeraldBest Practice & Research. Clinical Rheumatology|September 19, 2006
Spondyloarthropathy: disease at the crossroads of immunityOliver FitzGerald, Iain McInnesCurrent Rheumatology Reports|July 15, 2004
Tumor necrosis factor-alpha in psoriasis and psoriatic arthritis: a clinical, genetic, and histopathologic perspectiveDavid Kane, Oliver FitzGeraldArthritis Research & Therapy|February 24, 2009
Psoriatic arthritis: from pathogenesis to therapyOliver Fitzgerald, Robert WinchesterPageof 86